AP NEWS

Binge Disorders - Pipeline Insight, 2019 - ResearchAndMarkets.com

January 30, 2019

DUBLIN--(BUSINESS WIRE)--Jan 30, 2019--The “Binge Disorders - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Binge Disorders - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Binge Disorders development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Scope of the Report

The report provides a snapshot of the pipeline development for the Binge Disorders The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Binge Disorders The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Binge Disorders The report also covers the dormant and discontinued pipeline projects related to Binge Disorders

Topics Covered

1. Report Introduction

2. Binge Disorders Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Binge Disorders

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

Companies Featured

Sunovion Pharmaceutical Cannabics Pharmaceuticals Takeda Novonordisk

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/grlpx9/binge_disorders?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190130005646/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/30/2019 01:02 PM/DISC: 01/30/2019 01:01 PM

http://www.businesswire.com/news/home/20190130005646/en

AP RADIO
Update hourly